Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on February 10, 2021. The company is incorporated in Delaware and operates as an emerging growth company. Its common stock (CLRB) and warrants (CLRBZ) trade on the NASDAQ Capital Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial position or operations were reported in this filing. The document serves solely to disclose a scheduled corporate presentation.
Guidance, Outlook, and Management Commentary
Under Item 7.01 (Regulation FD Disclosure), the company announced that James Caruso, President and CEO, will present a company overview at the virtual 2021 BIO CEO & Investor Digital Conference. The event is scheduled to take place from February 16-18, 2021.
Key Facts for Investor Verification
- CEO James Caruso is scheduled to present at the 2021 BIO CEO & Investor Digital Conference (Feb 16-18, 2021).
- The press release regarding this presentation is attached as Exhibit 99.1.
- No financial data or operational updates were included in this specific filing.